- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
Eli Lilly's clinical trial results showed their pill was less effective than Wegovy, leading to market discussion among analysts and market watchers like Mizuho.
2 reports, 2 independent
Updated Aug 8
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly's clinical trial results showed their pill was less effective than Wegovy, leading to market discussion among analysts and market watchers like Mizuho.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.Also in this story
- Novo Nordisk and Eli Lilly are utilizing physician networks in Texas, including Carlos Campos, to promote their weight-loss drugs.
- UK MHRA approved Foundayo for commercialization, marking a significant market entry point in the global obesity drug competition.
- Bullish outlook for Eli Lilly due to strong sales momentum and durable patent coverage for its obesity treatment portfolio into the 2030s.
- Teva obtained FDA approval for a generic drug, challenging Novo Nordisk's market share in the GLP-1RA space.
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Eli Lilly and Novo Nordisk products are currently awaiting necessary approval from the Food and Drug Administration.
- Novo Nordisk, Merck, and Eli Lilly are noted as large pharmaceutical rivals with recent drug approvals and market presence in the US.
- Eli Lilly and Novo Nordisk are facing scrutiny regarding their name-brand weight loss drugs due to findings during an FDA data review.
Coverage
Newest first; wire copies grouped- Investing.comNovo shares rise for second day after Lilly obesity pills trails Wegovy in trial Investing.com - Copenhagen-listed shares of Novo Nordisk (CSE:NOVOb) rose by more than 5% on Friday, extending gains n
- BenzingaEli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuti